This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Alert me to new issues of the journal Download to citation manager Rights & Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Blayney, D. W. Search for Related Content PubMed Articles by Blayney, D. W.

Pricing, Reimbursement, and Health Care Trends to Watch

Because this article has no abstract, we have provided an extract of the first 100 words of the full text.

Douglas W. Blayney, MD

As part of your summer doldrums reading, follow me through two trends that are taking place on the medical pricing and reimbursement front. The first is the flurry of interest in erythropoetic stimulating agents (ESAs); the second is the transparency of primary care service pricing; and the last is the emergence of pharmacy benefit management organizations to assist in management of the expensive oral and home injectable anticancer agents we are using for our patients.

Left out of the recent debate about ESA pricing was a coherent overview of the relationship between manufacturer pricing, rebates to . . . [Click for More]